John Freund
Director/Board Member at SI-BONE, INC.
Net worth: 4 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Heffernan | M | 59 | 22 years | |
Garen Bohlin | M | 76 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 18 years |
Michael A. Pisetsky | M | 46 | 9 years | |
Jeffrey Dunn | M | 69 | 16 years | |
Jeryl Hilleman | F | 66 | 20 years | |
Gary Guthart | M | 58 | 28 years | |
Laura Francis | F | 57 | 9 years | |
Joseph Ciaffoni | M | 53 | 7 years | |
Jane Chung | F | 53 | 3 years | |
Dave Rosa Rosa | M | 56 | 28 years | |
Leonade D. Jones | F | 76 |
American Funds Fundamental Investors
Smallcap World Fund
The Growth Fund of America
| - |
Shirley Kuhlmann | F | 40 | 6 years | |
David N. Chernoff | M | - |
Crescendo Bioscience LLC
Crescendo Bioscience LLC Miscellaneous Commercial ServicesCommercial Services Crescendo Bioscience, Inc. develops and commercializes quantitative blood tests for rheumatoid arthritis and other autoimmune diseases. It develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. The company was founded by Mike B. Centola and Christopher L. Sutton in July 2002 and is headquartered in South San Francisco, CA. | - |
Jack D. Henion | M | - |
Advion BioSciences, Inc.
Advion BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Advion BioSciences, Inc. provides bioanalytical contract services to the pharmaceutical industry. Its clients include academic institutions, biotechnology, and pharmaceutical companies. Advion is the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their bioanalytical services and microfluidic chemistry systems. Its deep scientific expertise drives a product and services portfolio characterized by exceptional data quality, flexibility, speed, and regulatory compliance. Advion's excellence in method development provides a tremendous advantage in establishing reliable bioanalytical assays in a timely and cost-effective manner. Its expertise in technology development provides more information, better synthesis and mass analysis, higher yields, and substantially greater throughput. The company was founded in 1993 and is located in Ithaca, NY. | 31 years |
William Newell | M | 66 | 15 years | |
Joseph W. Powers | M | 65 | 15 years | |
Richard G. Capen | M | 89 |
Smallcap World Fund
| 31 years |
David Patteson | M | 69 |
Advion BioSciences, Inc.
Advion BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Advion BioSciences, Inc. provides bioanalytical contract services to the pharmaceutical industry. Its clients include academic institutions, biotechnology, and pharmaceutical companies. Advion is the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their bioanalytical services and microfluidic chemistry systems. Its deep scientific expertise drives a product and services portfolio characterized by exceptional data quality, flexibility, speed, and regulatory compliance. Advion's excellence in method development provides a tremendous advantage in establishing reliable bioanalytical assays in a timely and cost-effective manner. Its expertise in technology development provides more information, better synthesis and mass analysis, higher yields, and substantially greater throughput. The company was founded in 1993 and is located in Ithaca, NY. | - |
Linda Griego | F | 76 |
The Growth Fund of America
American Funds Fundamental Investors
Smallcap World Fund
| - |
Nikolas F. Kerr | M | 53 | 8 years | |
Nicki Vasquez | M | 61 | 9 years | |
Heidi Hunter | F | 66 | 3 years | |
Michael P. Ember | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 7 years |
Mika Nishimura | F | 60 | 3 years | |
Jon Wigginton | M | 62 | 4 years | |
Daniel Joseph Cher | M | - | 12 years | |
W. Carlton Reckling | M | 62 | 12 years | |
Rita Balice-Gordon | M | 63 | 4 years | |
Jeff Bertolini | M | - | 2 years | |
Helen Loh | F | 60 | 3 years | |
Neil McFarlane | M | 51 | 2 years | |
Michael Blanchard | M | - | 10 years | |
Anshul Maheshwari | M | 44 | 3 years | |
Scott Dreyer | M | 52 | 6 years | |
Lou Rassey | M | 50 |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | - |
Henry Heinsohn | M | - | - | |
Scott Sudduth | M | - | 6 years | |
Robyn Capobianco | M | - | 3 years | |
Myria Crawford | F | - |
Medivance, Inc.
Medivance, Inc. Medical SpecialtiesHealth Technology Medivance, Inc. develops, manufactures and markets therapeutic temperature management products. The company was founded in 1998 and is headquartered in Louisville, CO. | - |
Timothy Davis | M | 53 | 16 years | |
Connie Matsui | F | 70 | 5 years | |
James Panek | M | 71 | 4 years | |
Gino Santini | M | 66 | 12 years | |
Daniel Petree | M | 68 | - | |
Joseph Lobacki | M | 65 | 7 years | |
Gregory Hinckley | M | 77 | 13 years | |
Gwen Melincoff | M | 72 | 7 years | |
Michael Dybbs | M | 49 | 6 years | |
Linda Fitzpatrick | F | 67 | 16 years | |
Edward Albini | M | 66 | 11 years | |
Eric M. Gordon | M | 78 |
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California. | 22 years |
Ward S. McNally | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 17 years |
John Fallon | M | 76 | 8 years | |
Gary A. Carson | M | - |
Medivance, Inc.
Medivance, Inc. Medical SpecialtiesHealth Technology Medivance, Inc. develops, manufactures and markets therapeutic temperature management products. The company was founded in 1998 and is headquartered in Louisville, CO. | - |
Keith Valentine | M | 56 | 9 years | |
Joseph M. Kiely | M | - |
Advion BioSciences, Inc.
Advion BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Advion BioSciences, Inc. provides bioanalytical contract services to the pharmaceutical industry. Its clients include academic institutions, biotechnology, and pharmaceutical companies. Advion is the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their bioanalytical services and microfluidic chemistry systems. Its deep scientific expertise drives a product and services portfolio characterized by exceptional data quality, flexibility, speed, and regulatory compliance. Advion's excellence in method development provides a tremendous advantage in establishing reliable bioanalytical assays in a timely and cost-effective manner. Its expertise in technology development provides more information, better synthesis and mass analysis, higher yields, and substantially greater throughput. The company was founded in 1993 and is located in Ithaca, NY. | - |
Arun Padmanabhan | M | - | 7 years | |
David Pauling | M | - | - | |
Christopher James | M | - | 1 years | |
Kelly Clements | F | - | 2 years | |
Steve Shlensky | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | - |
Thomas Smith | M | 63 | 2 years | |
Craig Berman | M | - | 4 years | |
Diana Landa | F | - | 4 years | |
Troy S. Wahlenmaier | M | - | 12 years | |
Colleen Tupper | F | 48 | 3 years | |
Breaux B. Castleman | M | 83 |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 16 years |
Scott A. Yerby | M | 56 | 3 years | |
Anthony Recupero | M | 65 | 8 years | |
Ravi P Shah | M | - |
McNally Capital LLC
McNally Capital LLC Investment ManagersFinance McNally Capital LLC (McNally Capital) is a venture capital firm founded in 2008 by Ward S. McNally and John P. Rompon. The firm is headquartered in Chicago, Illinois. | 8 years |
Anne Borgman | M | 56 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Frederic Moll | M | 72 | 16 years | |
Larry G. Edwards | M | 52 | 5 years | |
Daniel T. Wallace | M | 57 | 6 years | |
Wendell Wierenga | M | 76 | 16 years | |
Vincent Angotti | M | 56 | 8 years | |
Ronald W. Barrett | M | 68 | 16 years | |
Robert G. Younge | M | 71 | 7 years | |
Guy L. de Chazal | M | 76 |
Morgan Stanley Venture Partners
Morgan Stanley Venture Partners Investment ManagersFinance Morgan Stanley Venture Partners (MSVP) is a venture capital firm subsidiary of Morgan Stanley Investment Management Merchant Banking, which is ultimately owned by Morgan Stanley (NYSE: MWD) founded in 1986.The firm is headquartered in New York.
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | 21 years |
William Rieflin | M | 64 | 12 years | |
Lonnie Smith | M | 79 | 23 years | |
Scott W. Borland | M | 53 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | - |
Gianna M. Bosko | F | 54 | 10 years | |
David M. Shaw | M | 57 | 6 years | |
Paul Brannelly | M | 51 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 11 years |
Gary C. Restani | M | 77 | 3 years | |
Mark A. Reiley | M | 74 | 11 years | |
Douglas Cole | M | 63 | 7 years | |
Ivan Delevic | M | 59 |
MAKO Surgical Corp.
MAKO Surgical Corp. Medical SpecialtiesHealth Technology MAKO Surgical Corp. is a medical device company, which develops and markets advanced robotic arm solution, joint specific applications for the knee, hip and orthopedic implants for orthopedic procedures. It also provides RIO robotic arm interactive orthopedic system, including a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The company was founded by Maurice R. Ferre and Rony A. Abovitz in November 2004 and is headquartered in Fort Lauderdale, FL. | 4 years |
Steven van Dick | M | 69 | 5 years | |
Lawrence G. Miller | M | 70 | 7 years | |
Daniel Janney | M | 58 | - | |
Guy MacDonald | M | 65 | 11 years | |
Russell C. Hirsch | M | 62 | 10 years | |
Timothy Nelson | M | 60 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 8 years |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 years |
Raymond McGuire | M | 67 |
Harvard College
Harvard Business School
| 9 years |
Alan Petro | M | - |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 3 years |
Steven J. Berger | M | - |
Harvard College
Harvard Business School
| 7 years |
Anand Gopal Mahindra | M | 69 |
Harvard College
Harvard Business School
| 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Freund
- Personal Network